{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T10:46:05Z","timestamp":1778841965840,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T00:00:00Z","timestamp":1625702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"DnaNudge"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>As SARS-CoV-2 testing expands, particularly to widespread asymptomatic testing, high sensitivity point-of-care PCR platforms may optimise potential benefits from pooling multiple patients\u2019 samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>We tested patients and asymptomatic citizens for SARS-CoV-2, exploring the efficiency and utility of CovidNudge (i) for detection in individuals\u2019 sputum (compared to nasopharyngeal swabs), (ii) for detection in pooled sputum samples, and (iii) by modelling roll out scenarios for pooled sputum testing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Across 295 paired samples, we find no difference (<jats:italic>p<\/jats:italic>\u00a0=\u20090.1236) in signal strength for sputum (mean amplified replicates (MAR) 25.2, standard deviation (SD) 14.2, range 0\u201360) compared to nasopharyngeal swabs (MAR 27.8, SD 12.4, range 6\u201356). At 10-sample pool size we find some drop in absolute strength of signal (individual sputum MAR 42.1, SD 11.8, range 13\u201360 vs. pooled sputum MAR 25.3, SD 14.6, range 1\u201354; <jats:italic>p<\/jats:italic>\u00a0&lt;\u20090.0001), but only marginal drop in sensitivity (51\/53,96%). We determine a limit of detection of 250 copies\/ml for an individual test, rising only four-fold to 1000copies\/ml for a 10-sample pool. We find optimal pooled testing efficiency to be a 12\u20133-1-sample model, yet as prevalence increases, pool size should decrease; at 5% prevalence to maintain a 75% probability of negative first test, 5-sample pools are optimal.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We describe for the first time the use of sequentially dipped sputum samples for rapid pooled point of care SARS-CoV-2 PCR testing. The potential to screen asymptomatic cohorts rapidly, at the point-of-care, with PCR, offers the potential to quickly identify and isolate positive individuals within a population \u201cbubble\u201d.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06316-z","type":"journal-article","created":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T18:03:08Z","timestamp":1625767388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pooled sputum to optimise the efficiency and utility of rapid, point-of-care molecular SARS-CoV-2 testing"],"prefix":"10.1186","volume":"21","author":[{"given":"Alison","family":"Burdett","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christofer","family":"Toumazou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashmita","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam","family":"Mujan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsz-Kin","family":"Hon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Bedzo-Nutakor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Casali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Karvela","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammadreza","family":"Sohbati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham S.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary W.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7095-7922","authenticated-orcid":false,"given":"Luke S. P.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"issue":"10268","key":"6316_CR1","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/S0140-6736(20)32635-0","volume":"397","author":"MC Fitzpatrick","year":"2021","unstructured":"Fitzpatrick MC, Pandey A, Wells CR, Sah P, Galvani AP. Buyer beware: inflated claims of sensitivity for rapid COVID-19 tests. Lancet. 2021;397(10268):24\u20135. https:\/\/doi.org\/10.1016\/S0140-6736(20)32635-0.","journal-title":"Lancet."},{"key":"6316_CR2","unstructured":"Public Health England. Preliminary report from the Joint PHE Porton Down and University of Oxford SARS-CoV-2 test development and validation cell: rapid evaluation of lateral flow viral antigen detection devices (LFDs) for mass community testing. Public Health England; 2021. Available from:\u00a0www.ox.ac.uk\/sites\/files\/oxford\/media_wysiwyg\/UK%20evaluation_PHE%20Porton%20Down%20%20University%20of%20Oxford_final.pdf. Accessed 23 Dec 2020."},{"issue":"7","key":"6316_CR3","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S2666-5247(20)30121-X","volume":"1","author":"MM Gibani","year":"2020","unstructured":"Gibani MM, Toumazou C, Sohbati M, Sahoo R, Icely C, Karvela M, et al. Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study. Lancet Microbe. 2020;1(7):300\u20137.","journal-title":"Lancet Microbe"},{"issue":"11","key":"6316_CR4","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1016\/S1473-3099(20)30362-5","volume":"20","author":"S Lohse","year":"2020","unstructured":"Lohse S, Pfuhl T, Berk\u00f3-G\u00f6ttel B, Rissland J, Gei\u00dfler T, G\u00e4rtner B, et al. Pooling of samples for testing for SARS-CoV-2 in asymptomatic people. Lancet Infect Dis. 2020;20(11):1231\u20132. https:\/\/doi.org\/10.1016\/S1473-3099(20)30362-5.","journal-title":"Lancet Infect Dis"},{"key":"6316_CR5","unstructured":"United States of America Food and Drug Administration. Molecular Diagnostic Template for Commercial Manufacturers. FDA; 2020. Available from:\u00a0https:\/\/www.fda.gov\/medical-devices\/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices\/vitro-diagnostics-euas. Accessed 23 Dec 2020."},{"key":"6316_CR6","unstructured":"Public Health England. Pooling of asymptomatic SARS COV-2 COVID-19 samples for (PCR\/or other) testing. Public Health England; 2020. Available from:\u00a0https:\/\/www.england.nhs.uk\/coronavirus\/publication\/pooling-of-asymptomatic-sars-cov-2-covid-19-samples-for-pcr-or-other-testing\/. Accessed 23 Dec 2020."},{"key":"6316_CR7","doi-asserted-by":"publisher","first-page":"102903","DOI":"10.1016\/j.ebiom.2020.102903","volume":"59","author":"A Mohammadi","year":"2020","unstructured":"Mohammadi A, Esmaeilzadeh E, Li Y, Bosch RJ, Li JZ. SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis. EBioMedicine. 2020;59:102903. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102903.","journal-title":"EBioMedicine."},{"key":"6316_CR8","unstructured":"Public Health England. COVID-19: investigation and initial clinical management of possible cases. Public Health England; 2020. Available from:\u00a0https:\/\/www.gov.uk\/government\/publications\/wuhan-novel-coronavirus-initial-investigation-of-possible-cases\/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection. Accessed 23 Dec 2020."},{"key":"6316_CR9","unstructured":"DNAgenotek. Inactivation of SARS-CoV-2 in samples using Oragene, ORAcollect, and OMNIgene products from DNAgenotek. DNAgenotek; 2020. Available from:\u00a0https:\/\/www.dnagenotek.com\/US\/pdf\/MK-01430.pdf. Accessed 23 Dec 2020."},{"issue":"9","key":"6316_CR10","doi-asserted-by":"publisher","first-page":"e0239492","DOI":"10.1371\/journal.pone.0239492","volume":"15","author":"AK Singh","year":"2020","unstructured":"Singh AK, Nema RK, Joshi A, Shankar P, Nema S, Raghuwanshi A, et al. Evaluation of pooled sample analysis strategy in expediting case detection in areas with emerging outbreaks of COVID-19: a pilot study. PLoS One. 2020;15(9):e0239492. https:\/\/doi.org\/10.1371\/journal.pone.0239492.","journal-title":"PLoS One"},{"issue":"1","key":"6316_CR11","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1186\/s12879-020-05446-0","volume":"20","author":"JJ Cabrera Alvargonzalez","year":"2020","unstructured":"Cabrera Alvargonzalez JJ, Rey Cao S, P\u00e9rez Castro S, Martinez Lamas L, Cores Calvo O, Torres Pi\u00f1on J, et al. Pooling for SARS-CoV-2 control in care institutions. BMC Infect Dis. 2020;20(1):745. https:\/\/doi.org\/10.1186\/s12879-020-05446-0.","journal-title":"BMC Infect Dis"},{"issue":"11","key":"6316_CR12","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/S2213-2600(20)30444-6","volume":"8","author":"A Fogarty","year":"2020","unstructured":"Fogarty A, Joseph A, Shaw D. Pooled saliva samples for COVID-19 surveillance programme. Lancet Resp Med. 2020;8(11):1078\u201380. https:\/\/doi.org\/10.1016\/S2213-2600(20)30444-6.","journal-title":"Lancet Resp Med."},{"issue":"1","key":"6316_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1186\/s12879-021-06061-3","volume":"21","author":"SA Mahmoud","year":"2021","unstructured":"Mahmoud SA, Ibrahim E, Thakre B, Teddy JG, Raheja P, Ganesan S, et al. Evaluation of pooling of samples for testing SARS-CoV- 2 for mass screening of COVID-19. BMC Infect Dis. 2021;21(1):360. https:\/\/doi.org\/10.1186\/s12879-021-06061-3.","journal-title":"BMC Infect Dis"},{"issue":"12","key":"6316_CR14","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1016\/S2213-2600(20)30451-3","volume":"8","author":"LSP Moore","year":"2020","unstructured":"Moore LSP. Near-patient SARS-CoV-2 molecular platforms: new-old tools for new-old problems. Lancet Resp Med. 2020;8(12):1161\u20133. https:\/\/doi.org\/10.1016\/S2213-2600(20)30451-3.","journal-title":"Lancet Resp Med"},{"issue":"19","key":"6316_CR15","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1001\/jama.2020.5445","volume":"323","author":"CA Hogan","year":"2020","unstructured":"Hogan CA, Sahoo MK, Pinsky BA. Sample pooling as a strategy to detect community transmission of SARS-CoV-2. JAMA. 2020;323(19):1967\u20139. https:\/\/doi.org\/10.1001\/jama.2020.5445.","journal-title":"JAMA."},{"issue":"11","key":"6316_CR16","doi-asserted-by":"publisher","first-page":"e0241959","DOI":"10.1371\/journal.pone.0241959","volume":"15","author":"MG Becker","year":"2020","unstructured":"Becker MG, Taylor T, Kiazyk S, Cabiles DR, Meyers AF, Sandstrom PA. Recommendations for sample pooling on the Cepheid GeneXpert\u00ae system using the Cepheid Xpert\u00ae Xpress SARS-CoV-2 assay. PLoS One. 2020;15(11):e0241959. https:\/\/doi.org\/10.1371\/journal.pone.0241959.","journal-title":"PLoS One"},{"issue":"5","key":"6316_CR17","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1002\/jmv.26632","volume":"93","author":"F Chen","year":"2021","unstructured":"Chen F, Geng Z, Wang J, Liuchang W, Huang D, Xu Y, et al. Comparing two sample pooling strategies for SARS-CoV-2 RNA detection for efficient screening of COVID-19. J Med Virol. 2021;93(5):2805\u20139. https:\/\/doi.org\/10.1002\/jmv.26632.","journal-title":"J Med Virol"},{"issue":"12","key":"6316_CR18","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.cmi.2020.07.015","volume":"26","author":"K Skolimowska","year":"2020","unstructured":"Skolimowska K, Rayment M, Jones R, Madona P, Moore LSP, Randell P. Non-invasive saliva specimens for the diagnosis of COVID-19: caution in mild outpatient cohorts with low prevalence. Clin Microbiol Infect. 2020;26(12):1711\u20133. https:\/\/doi.org\/10.1016\/j.cmi.2020.07.015.","journal-title":"Clin Microbiol Infect"},{"issue":"12","key":"6316_CR19","first-page":"7173","volume":"24","author":"VH Pham","year":"2020","unstructured":"Pham VH, Gargiulo Isacco C, KCD N, Le SH TDK, Nguyen QV, Pham HT, et al. Rapid and sensitive diagnostic procedure for multiple detection of pandemic Coronaviridae family members SARS-CoV-2, SARS-CoV, MERS-CoV and HCoV: a translational research and cooperation between the Phan Chau Trinh University in Vietnam and University of Bari \u201cAldo Moro\u201d in Italy. Eur Rev Med Pharmacol Sci. 2020;24(12):7173\u201391.","journal-title":"Eur Rev Med Pharmacol Sci"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06316-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06316-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06316-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T18:05:04Z","timestamp":1625767504000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06316-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6316"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06316-z","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"22 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Chelsea & Westminster NHS Foundation Trust COVID testing committee. The study was reviewed by the Chelsea & Westminster NHS Foundation Trust Research and Development Office and deemed a verification of a CE marked in vitro diagnostic test, therefore the need individual informed consent was waived. Aggregated data was analysed in accordance to the UK Secretary of State for Health and Social Care general notice that under the Health Service Control of Patient Information Regulations (2002) patient data for a COVID-19 purposes may be used for research. The study was conducted in accordance with relevant guidelines and regulations including the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publication of this manuscript in this journal. This work has not been previously published in any other journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AB, CT, RS, NC, AM, MS, MK, T-KH and JB are employees of DnaNudge. CT is the co-inventor of the DnaNudge CovidNudge system and is named on the patent for the method and apparatus for analysing biological specimens on the DnaNudge platform (US Patent No: US 10 093 965.B2). LSPM has consulted for and\/or received speaker fees from bioMerieux (2013\u20132021), Pfizer (2018\u20132021), Eumedica (2016\u20132021), Umovis Lab (2020\u20132021), Shionogi (2021), Pulmocide (2021), DNAelectronics (2015\u201318), and Dairy Crest (2017\u20132018), received research grants from the National Institute for Health Research (2013\u20132019), and CW+ Charity (2018\u20132021). GC is an NIHR research professor and investigator within the NIHR London in-vitro diagnostic co-operative. All other authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"665"}}